Table 1.
38-gene HGF status, patient, and clinical characteristics among Carolina Breast Cancer Study participants by study phase (CBCS-1/2, 1993–2001; CBCS-3, 2008–2013)
| CBCS 1 & 2 (N=706) | CBCS 3 (N=1251) | |||
|---|---|---|---|---|
| HGF Negative (N=428) |
HGF Positive (N= 278) |
HGF Negative (N= 901) |
HGF Positive (N=350) |
|
| Race | ||||
| Black | 171 (40%) | 179 (64%) | 432 (48%) | 251 (72%) |
| Non-Black | 257 (60%) | 99 (36%) | 469 (52%) | 99 (28%) |
| Age at diagnosis | ||||
| < 50 | 208 (49%) | 181 (65%) | 442 (49%) | 211 (60%) |
| 50+ | 220 (51%) | 97 (35%) | 459 (51%) | 139 (40%) |
| ER status | ||||
| Positive | 315 (74%) | 54 (20%) | 798 (90%) | 67 (21%) |
| Negative | 108 (26%) | 221 (80%) | 89 (10%) | 253 (79%) |
| PAM50 | ||||
| Luminal A | 283 (69%) | 20 (8%) | 535 (62%) | 11 (3%) |
| Luminal B | 74 (18%) | 6 (2%) | 214 (25%) | 13 (4%) |
| HER2- Enriched | 40 (10%) | 23(9%) | 82 (9%) | 35 (10%) |
| Basal | 13 (3%) | 216 (81%) | 32 (4%) | 277 (83%) |
| Stage** | ||||
| Stage I | 152 (38%) | 74 (28%) | 347 (40%) | 84 (25%) |
| Stage II | 208 (52%) | 164 (62%) | 397 (46%) | 185 (55%) |
| Stage III | 40 (10%) | 25 (10%) | 124 (14%) | 67 (20%) |
| Grade* | ||||
| I/II | 86 (62%) | 28 (26%) | 605 (68 %) | 43 (12%) |
| III | 52 (38%) | 81 (74%) | 285 (32%) | 303 (88%) |
| BMI | ||||
| Median BMI (IQR) | 27.10 (8.85) | 28.99 (9.50) | 29.66 (9.73) | 30.52 (9.30) |
| Family history of breast cancer | ||||
| Yes | 346 (83%) | 217 (82%) | 707 (81%) | 280 (82%) |
| No | 73 (17%) | 49 (18%) | 162 (19%) | 61 (18%) |
*
Tumor grade was not collected in CBCS-2 and therefore was missing from 454 participants in CBCS-2. Tumor grade was missing from less than 2% of patients in CBCS-1 & CBCS-3.
**
Stage 4 women were excluded (<3% for CBCS-1/2, <4% CBCS-3)
IQR: Interquartile range; ER: Estrogen receptor; BMI: Body Mass Index;